Clinuvel Pharmaceuticals Ltd (CUVL)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $4.90
- As of
Kresmion compiles this page from CUVL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Clinuvel Pharmaceuticals Ltd (CUVL): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 20-F filed 2026-10-30.
See the full CUVL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CUVL on one page. Preview it with sample data, then open it live with a free account.
Preview the CUVL dossierActive events for CUVL
- mediumEarnings below estimates
Q4-2026: Missed consensus by 8.8%, EPS $0.462 vs $0.5065 estimate
FREE, NO ACCOUNT
Every event on CUVL, as it fires
New filings, 13F moves and cross asset events on CUVL land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter.
Recent SEC filings, CUVL
- 20-FSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
More data on CUVL
CUVL against its peers
CUVL's operating margin of 43.4% ranks in the 97th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | CUVL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 64.3M USD | 13.8M USD | 71 | 18 |
| Gross margin | 82.9% | n/a | n/a | 2 |
| Operating margin | 43.4% | -251.6% | 97 | 15 |
| Net margin | 36.0% | -301.7% | 91 | 15 |
| Return on equity | 12.3% | -40.5% | 93 | 21 |
| 1 year | n/a | -23.9% | n/a | 23 |
Peers (23): PLX, RCKT, INO, SABS, QTTB, NWBO, PRLD, VNDA, ARCT, IMRX, CABA, CAMP, ALLO, BCYC, OCGN, LXEO, LCTX, DTIL, EVMN, TTRX, NAUT, EBS, IPSC. Left out: VOGX (no annual filing), DRUG (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (CUVL: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in CUVL on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on CUVL in the last 180 days.
Upstream: SEC EDGAR filings for CUVL
Kresmion, "Clinuvel Pharmaceuticals Ltd (CUVL) institutional holdings and SEC filings", data as of 2026-10-30, https://kresmion.com/research/CUVL. Upstream data: SEC EDGAR filings for CUVL.
Link to this data (HTML):
<a href="https://kresmion.com/research/CUVL">Clinuvel Pharmaceuticals Ltd (CUVL) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow CUVL on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to CUVL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.